Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation.

Subject matter of the present invention is a method for determining the fat processing activity and/or predicting the risk of obesity in a subject. The method involves determining the level of pro-neurotensin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from a subject; and correlating the determined level of pro-neurotensin or fragments thereof with fat processing activity and/or the risk of incidence of obesity in the subject, wherein an elevated level is indicative of enhanced fat processing activity and/or predictive for an enhanced risk of getting obesity.

The present invention relates to a method of diagnosing or prognosing a metabolic disorder in a subject; and in particular to a method comprising determining the quantitative or qualitative level of a biomarker in a biological sample; and diagnosing or prognosing the metabolic disorder based on the quantitative or qualitative level of the biomarker.

Subject matter of the present invention is a method for determining the fat processing activity and/or predicting the risk of obesity in a subject comprising the following steps determining the level of pro-neurotensin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said subject; and correlating said level of pro-neurotensin or fragments thereof with fat processing activity and/or the risk of incidence of obesity in said subject, wherein an elevated level is indicative of enhanced fat processing activity and/or predictive for an enhanced risk of getting obesity.

The present invention relates to a method for measuring the cholesterol uptake capacity of lipoproteins. The present invention also relates to a reagent kit for measuring the cholesterol uptake capacity of lipoproteins. The present invention further relates to a tagged cholesterol which can be used in the method and the reagent kit.

The present invention provides ELISA-based methods for detecting and/or quantifying ANGPTL8 in biological samples using anti-ANGPTL8 antibodies.

The present invention is related to an in vitro method for diagnosing Gaucher's disease in a subject comprising a step of a) detecting a biomarker in a sample from the subject, wherein the biomarker is free lyso-Gb1.

Described herein are inhibitors Transient Receptor Potential Canonical (TRPC) ion channels comprising TRPC4 protein and/or TRPC5 protein for use in combating obesity and other medical conditions including insulin resistance associated with Type II diabetes or development of Type II diabetes (pre-diabetes), metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Also disclosed is the use of the inhibitors for cosmetic purposes, such as cosmetic weight loss.

A method for preventing obesity related to infection by an adipogenic adenovirus includes obtaining a sample from a person, assaying the sample to determine whether the person has been previously infected with an adipogenic adenovirus, and if the person has not been previously infected, providing the person with at least one sensor positioned to detect when a person's hand approaches a predetermined distance from the person's face. By warning the person of undesired hand-to-face contacts, the person is able to reduce the incidence of obesity related infections. Other embodiments are directed to a kit for preventing obesity caused by infection with an adipogenic adenovirus, such kit including a container for assaying an agent indicating the presence of antibodies to Ad-36, and a sensor positioned on an item selected from the group consisting of one of a hat, a writing instrument, eye glasses, a belt, sunglasses, a bra, a shirt, and a tie.

The present invention relates to a method for measuring the cholesterol uptake capacity of lipoproteins. The present invention also relates to a reagent kit for measuring the cholesterol uptake capacity of lipoproteins. The present invention further relates to a tagged cholesterol which can be used in the method and the reagent kit.